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Laura Orsolini 1,2*, Irena Rojnić Palavra 3, Gabriele Duccio Papanti 4, Matej Potočan 5,
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Background: Although psychoactive substance use disorders (PSUDs) are a domain of
mental health, addiction psychiatry is only formally recognized as a subspecialty in a few
European countries, and there is no standardized training curriculum.
Methods: A 76-item questionnaire was developed and disseminated through an online
anonymous data-collecting system and hand-to-hand amongst psychiatric trainees from
the 47 European countries of the Council of Europe plus Israel and Belarus.
Results: 1,049/1,118 psychiatric trainees from 30 European countries completed
the questionnaire. Fifty-nine-point nine percent of trainees stated to have training in
addictions. Amongst the trainees who described having training in addictions, 43%
documented a not well-structured training and 37% an unsatisfactory training, mainly due
to poor acquired knowledge. Overall, 97% of trainees stated that addiction represents a
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core curriculum for their training. Overall, general adult psychiatric trainees reported a
better knowledge in addictions, compared to trainees in child and adolescent psychiatry.
Conclusion: Despite a growing spread of PSUDs in European countries, addiction
psychiatry is a relatively poorly trained field within psychiatry training programs. Further
research should investigate reasons for poor training and timings of the educational
activities to optimize experiential education training in addiction psychiatry.
Keywords: addiction psychiatry, addiction, EFPT, psychiatry trainees, psychiatry training
INTRODUCTION
According to the Global Burden Disease study (1), alcohol,
tobacco, and illicit substance use significantly determine the
global burden of disability, morbidity and mortality, being
considered amongst the top four health burdens across many
upper-middle and high-income countries. Mental and behavioral
disorders due to psychoactive substance use include different
conditions caused by the intake of medically or not medically
prescribed psychoactive substances (2). Psychoactive substance
use disorder (PSUD) was firstly coded as a discrete diagnostic
category both in the American Psychiatric Association (APA)
Diagnostic and Statistical Manual (DSM)-3rd edition (DSM-III)
and in the World Health Organization (WHO) International
Classification of Diseases and Related Health Problems (ICD)-
9th edition of the (2–4). The current Diagnostic and Statistical
Manual-5th edition (DSM-5) (5) amalgamated the abuse and
dependence under a single category named “Substance Use
Disorder” whilst the ICD-11 beta draft (6) described substance
dependence (not substance use) (ICD: F10.xx to F19.xx)
as a “disorder of regulation of the use of a psychoactive
substance arising from repeated or continuous use of the
substance [. . . ]” (5, 6). Overall, PSUD may largely differ in
severity and intensity in their psychopathological and clinical
manifestation, i.e., ranging from an uncomplicated intoxication
to the development of clinically significant psychotic disorders or
other psychopathological and/or clinical manifestations) (2).
People with PSUD, including those classified as affected
with a dual disorder, have been considered, compared to
the general population, at higher risk of developing a range
of medical and psychiatric disorders in comorbidity (7–9).
Overall, PSUD subjects, particularly those with concurrent
mental disorders, are overall associated with poorest outcomes,
higher psychopathological severity and an increased rate of
risky behaviors (i.e., hypersexuality, syringes/needles sharing,
etc.) which can predispose them to an increased occurrence
of serious infection diseases like Human Immunodeficiency
Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) and
Hepatitis C Virus (HCV), compared to the general population
(10). Moreover, people with PSUD display a worsen psychosocial
impairment (e.g., unemployment and homelessness) and they
can more likely be involved in criminal and antisocial behaviors,
compared to people affected by other mental disorders with a
concurrent substance and/or alcohol use disorder (8, 11, 12).
However, although the PSUDs are fully considered among
the mental and behavioral disorders, the contribution of
psychiatrists, early career psychiatrists (ECPs) and psychiatry
trainees into this clinical and research field, should be better
developed. For instance, addiction psychiatry (sometimes named
as addiction medicine) appears not to be adequately and
homogeneously incorporated within the psychiatric training,
across all European countries. Furthermore, psychiatry trainees’
levels of knowledge and experiences in addiction psychiatry may
greatly vary across European countries and cultures. As already
documented by the 2014 WHO Global Survey on Resources
for Prevention and Treatment of Substance Use Disorders,
around 37% of the 155 responding countries do not provide
adequate access to the post-graduate training programme for
professionals working in PSUD treatment (13). Globally almost
30% of countries did not report a dedicated training programme
for the treatment and the management of PSUD patients (52% of
low-income countries vs. 16% of high-income countries), being
mainly included in a short cycle tertiary education programme
(48%). Overall, 95% of countries documented that psychiatrists
are commonly involved in the treatment of people with PSUD,
followed by psychologists, who are involved in PSUD treatment
and management in around 86% of the countries. Furthermore,
more than 80% of European countries reported the availability
of a post-graduate training programme for the treatment and
management of PSUD for psychiatrists (14).
Contextually, psychiatrists and psychiatry trainees’ attitudes
toward PSUD patients largely differ across different countries
and cultures, where people with PSUD are generally more
exposed to psychiatrists’ and health professionals’ negative
attitudes/perception as well stigmatizing behaviors, and
language (15). Stigmatizing behaviors and attitudes displayed
by both psychiatrists and other physicians may lead to an
inadequate and inhomogeneous physical, mental health care
and treatment, including prescribing non evidence-based
pharmacological/not pharmacological treatments, prescribing
an inadequate/insufficient posology and duration of therapy.
Moreover, use of potentially stigmatizing language may lead
mental health professionals to a poor/inadequate communication
with their PSUD patients, displaying an overall judgmental and
unempathetic attitude, and other problematic and potentially
stigmatizing behaviors (16–19).
The present study aimed at evaluating the organization of
the addiction psychiatry training, trainees’ satisfaction, trainees’
attitudes toward people who use psychoactive substances and
addiction psychiatry, and how psychiatric trainees manage
psychopharmacology and pharmacotherapy in the most
common clinical presentations of people with PSUD and
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The EFPT-PSUD Study has been an international cross-sectional
survey of European psychiatry trainees carried out in the context
of the European Federation of Psychiatric Trainees (EFPT), the
umbrella organization of the national trainees’ associations in
psychiatry in Europe (20, 21). Among the framework of the EFPT,
a working group specifically dedicated to the PSUD developed a
self-administered survey that was disseminated at European level,
by involving both Child and Adolescent Psychiatry (CAP) and
General Adult Psychiatric (GAP) trainees.
Pilot Phase
All active members of the EFPT-PSUD Working Group,
constituted during the 2014 EFPT Forum in London (22) and
initially comprising national representatives from 5 countries
(Italy, Croatia, Lithuania, Denmark, and Estonia), firstly
conducted a preliminary overview about the current state-of-the-
art regarding the training in addiction psychiatry in the European
CAP/GAP training programs, and subsequently developed the
survey. The survey was initially piloted amongst the members of
the EFPT-PSUDWorking Group.
Full Study Phase
The previously developed survey was circulated at the European
level both to CAP and GAP trainees. The survey was circulated
to the national representatives of each 47 European countries of
the Council of Europe plus Israel and Belarus.
The European countries not represented in the survey were
those not able to identify a National Coordinator who would take
over the responsibility of the study or those unable to collect at
least 10 completed questionnaires from their own country.
Instrument
The questionnaire was a 76-item self-report survey (Appendix 1
in the Supplementary Material). The questionnaire consisted
of: (a) single answer and/or multiple answer questions (i.e.,
for evaluating trainees’ knowledge in a specific field); (b) an
increasing five-item Likert scale (i.e., for evaluating attitudes
and interests toward the addiction medicine and psychiatry);
and, (c) a series of open-ended questions (i.e., asking for
further specification and/or clarification of the provided
answers). In particular, the section on general knowledge on
addiction consists of 36 items in which each question correctly
answered gave 1 point (range score: 0–36). This section was
developed by GDP, following the evidence-based practices of
the Substance Abuse and Mental Health Services Administration
(SAMHSA) (https://www.samhsa.gov/ebp-resource-center).
For the present article, we have focused on the following
sections of the survey:
• General socio-demographic section;
• General information about training in GAP (General Adult
Psychiatry) or Child and Adolescent Psychiatry (CAP),
including experiences (if any) on addiction psychiatry;
• General attitudes and interest toward addictions,
addiction psychiatry;
• Level of knowledge about addictions, addictive disorders,
including treatment.
Data Collection
One national coordinator per each of 47 European countries
of the Council of Europe plus Israel and Belarus facilitated the
delivery of the survey through an online data collecting system
(https://www.surveymonkey.com/r/EFPT-PSUDstudy) and/or, if
necessary, delivering the questionnaire hand-by-hand, in a
paper form (Appendix 1). The questionnaire was circulated in
English across all European countries (in French language in
France) and no translation in other languages was deemed
necessary, as psychiatric trainees were deemed by their
national coordinators to have sufficient command of English
to reliably answer the questions (i.e., this was preliminarily
evaluated by each national coordinator). Data were collected
from 15th August 2015 to 15th October 2016. Annual
EFPT forum as well as European and national congresses
or educational events were chosen to reach out to all
CAP/GAP trainees in each country or to involve national
coordinators, needed for those countries still not represented
in the sample of the survey. Moreover, European contact
e-mail databases were periodically used to disseminate the
link for the online survey (https://www.surveymonkey.com/r/
EFPT-PSUDstudy). All hand-to-hand questionnaires completed
were subsequently entered into the online study database
by the National Coordinator via the online survey tool
Survey Monkey. The online survey link was only accessible
by invitation.
Inclusion Criteria
The inclusion criteria were: (i) being a CAP/GAP trainee, defined
as a fully qualified medical doctor enrolled in a nationally
recognized specialist training programme in CAP or GAP; (ii)
belonging to one of the 47 European countries of the Council of
Europe plus Israel and Belarus.
The participant countries included in the present analysis were
those countries of whom each CAP/GAP National Coordinator
was able to collect at least 10 completed questionnaires [not
considering the last section regarding Novel Psychoactive
Substances (NPS)]. Those countries with a National Coordinator
who took responsibility to take part in the study but did not reach
an enough minimum number of completed questionnaires were
excluded in the present analysis (Greece, Belgium, Germany,
Slovakia, Ukraine, Sweden, Denmark, and Israel). Amongst
these, the following European countries participated in the
present survey with a valid number of filled questionnaires:
Albania, Austria, Azerbaijan, Belarus, Bosnia and Herzegovina,
Bulgaria, Croatia, Czech Republic, Estonia, Finland, France,
Hungary, Ireland, Italy, Kosovo, Latvia, Lithuania, Moldova,
Netherlands, Norway, Poland, Portugal, Romania, Russia, Serbia,
Slovenia, Spain, Switzerland, Turkey, and UK.
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Ethics Approval and Consent
The survey was conducted according to the principles of good
scientific practice, which was supported by previous EFPT-
sponsored psychiatry trainees’ surveys (23). Ethical approval
for the study has been sought and granted by the School of
Pharmacy Ethics Committee at the University of Hertfordshire
(December 15, 2010, reference code PHAEC/10-42), with a
further extension of the approval granted in November 2013.
The patients/participants provided their written online informed
consent to participate in this study.
Before filling out the survey which was self-administered
anonymously, all participants were asked to give written online
informed consent before, as legally and ethically required.
Statistical Analysis
Data was analyzed using the Software Package for Social
Sciences for Windows v. 24.0 (SPSS 24) (IBM Corp, Armonk
NY). Categorical variables were summarized as n (%), and
continuous variables as means [standard deviation (SD)].
Pearson’s χ2-tests were used to compare demographic and
categorical variables, such as the trainees’ attitudes toward
addiction psychiatry. Student’s t-tests and one-way analysis
of variance (ANOVA)-tests were used to compare continuous
variables, including comparisons of training experiences. Ordinal
regression was used to model the predictors of trainee
satisfaction. Variables added to the model included trainees’
sub-specialty and percentage of training completed. The
significance level was set a priori at p ≤ 0.05, and all hypotheses
were two-tailed.
RESULTS
Sampling and Sample Characteristics
The total number of questionnaires correctly filled during
the collection process and afterwards included in the analysis
was of 1,118, amongst all trainees in Europe who took part
in the survey. However, after excluding missing data (i.e.,
including only complete questionnaires) only 1,049 responses
were included (Table 1). There were differences in the gender
distribution, being most of them women (68.7%) and this
difference is statistically significant when we stratified the
sample by subspecialty (χ2 = 25, p < 0.001), being 84.6% of
the CAP sample represented by women, whilst in the GAP
sample, a percentage of 64% was represented by women, by
reaching a total amount of GAP and CAP trainees of 936 (after
excluding those trainees in forensic psychiatry or others with
an unspecified other psychiatry training). The mean age of
respondents was 30.48 (±4.84) years, without any statistically
significant differences between GAP and CAP samples. The
majority (73.8%) were GAP trainees, whereas 15.4% were CAP
trainees, whilst around 10.6% of the sample did not specify
if they are GAP or CAP trainees. Amongst the respondents,
the total number of years required to complete GAP and CAP
training programs may largely differ across European countries.
To adjust the analysis for this confounder, it was calculated the
percentage of progression/completeness of individual training
for each country, in order to measure the most reliable and
objective variable. This variable reported that in an average
of 67.4% of the total sample, CAP/GAP trainees were in
the last quantile of their training programme, without any
statistically significant difference between GAP and CAP (see
Figure 1). The CAP/GAP trainees overall belong to 30 different
countries, with the highest proportion of respondents amongst
those training in France (16.3%), followed by Italy (5.7%),
Spain (5.1%) and the UK (5.0%). See Table 1 for further
demographic features.
Trainees’ Experience, Satisfaction, and
Training in Addiction Psychiatry
Amongst those who answered the question “Have you performed
part of your psychiatric training in the treatment of patient
with substance use disorder?”, only 59.9% of trainees reported
to have spent part of their training in addiction psychiatry
settings, with a statistically significant difference between GAP
and CAP trainees (p = 0.018). Amongst those trainees who
declared to have received training in addiction psychiatry during
their psychiatry training, only 43% described that the PSUD
training was not well-structured due to several reasons. First, the
addiction training program is often too short to allow trainees
to deepen knowledge on all theoretical and practical aspects
of addiction psychiatry; second, during the addiction training
program, CAP/GAP trainees are often alone in the management
of PSUD patients (often without a dedicated supervisor/mentor);
third, the addiction training program usually consists in a
mere observership experience (without a practical frontline
experience). Amongst those trainees who had training in
addictions only 37% of them declared that they were not
satisfied about the level of training offered, mainly stating lack of
enough acquired skills and knowledge in the field, largely below
their initial expectations. There was no significant difference in
the percentage of training completed amongst those trainees
who reported being satisfied with their addiction psychiatry
training, compared to those trainees who did not document
an enough level of satisfaction [F(1,555) = 2.244, p= 0.135].
Trainees with larger caseloads had generally progressed further in
their training, compared to those trainees with smaller caseloads
[F(5,551) = 6.487, p < 0.001]. Most of the sample (97%) agreed or
strongly agreed that addiction represents a core curriculum for
training. Subspecialty was a significant predictor of satisfaction
with training (β = 1.713; p = 0.042), being GAP trainees overall
more satisfied, compared to CAP trainees, even though this
finding is not strictly correlated by the percentage of training
completed (β = 1.005; p= 0.176).
Trainees’ Attitudes Towards People Who
Use Psychoactive Substances and
Addiction Psychiatry
Approximately one third of the sample (33.27%) agreed
or strongly agreed to be confident with their basic skills
needed/requested necessary to work in addiction settings after
their training (χ2 = 82.864; p< 0.001). Interestingly, on the other
hand, around 66.9% of the trainees agreed or strongly agreed
that “Addiction psychiatrists are usually less skilled than their
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TABLE 1 | Demographic characteristics.
Total GAP (N = 774) CAP (N = 162) Significance
Mean (SD) Mean (SD) Mean (SD) t
Age 30.48 (4.84) 30.43 (4.58) 30.79 (5.24) p = 0.899
Training completed (%) 67.37 (28.01) 67.77 (28.44) 66.95 (28.64) p = 0.716
Frequency (%) Frequency (%) Frequency (%) χ2
Gender p < 0.001
Male 328 (31.3%) 269 (34.8%) 25 (15.4%)
Female 721 (68.7%) 505 (65.2%) 137 (84.6%)
Country of training p = 0.221
Croatia 38 (3.6%) 26 (3.4%) 5 (3.1%)
Czech Republic 36 (3.4%) 28 (3.65%) 8 (4.9%)
Finland 44 (4.2%) 32 (4.1%) 8 (4.9%)
France 171 (16.3%) 101 (13.0%) 30 (18.5%)
Ireland 40 (3.8%) 20 (2.6%) 5 (3.1%)
Italy 57 (5.4%) 50 (6.5%) 7 (4.3%)
Lithuania 45 (4.3%) 35 (4.5%) 10 (6.2%)
Netherlands 35 (3.3%) 23 (3.0%) 3 (1.9%)
Poland 47 (4.5%) 38 (4.9%) 6 (3.7%)
Portugal 42 (4.0%) 37 (4.8%) 5 (3.1%)
Romania 45 (4.3%) 39 (5.0%) 6 (3.7%)
Slovenia 33 (3.1%) 22 (2.8%) 9 (5.6%)
Spain 53 (5.1%) 47 (6.1%) 1 (0.6%)
Switzerland 34 (3.2%) 27 (3.5%) 7 (4.3%)
Turkey 40 (3.8%) 31 (4.0%) 9 (5.6%)
UK 52 (5.0%) 30 (3.9%) 5 (3.1%)
Other 237 (22.6%) 188 (24.3%) 38 (23.5%)
GAP, General Adult Psychiatry; CAP, Child and Adolescent Psychiatry; SD, Standard Deviation; UK, United Kingdom.
FIGURE 1 | Distribution of training completion.
colleagues working in GAP/CAP” (Table 2). Moreover, around
75.7% disagreed or strongly disagreed that addictions are mental
disorders; similarly, 77.8% of the sample agreed or strongly
agreed that people with drug addiction cannot be recovered
(Table 2).
Over three-quarters of respondents (76.1%) knew/had
previously known someone outside of their workplace with an
addiction-related problem (Table 3). The findings showed that
those who knew/had known someone with addiction related
problems were significantly associated with a stronger desire to
work in the addictions after their training [χ2(4) = 16.311, p =
0.003] (Figure 2).
Trainees’ Basic Knowledge and
Confidence/Perceived Competence in
Addiction Psychiatry
Respondents who had treated someone with an addiction-related
condition significantly declared to have almost completed their
training, compared to those trainees who had not [F(1,991) =
99.155, p < 0.001] (Figure 3). Figure 4 represents the graphical
distribution of the knowledge score, by indicating that most
trainees responded correctly to most of the questions regarding
their general and specific knowledge of addiction psychiatry
(mean average 25.77 ± SD 3.59), with a minimum score of
7 and a maximum score of 34 (skewness = −0.956). There
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TABLE 2 | Attitude of trainees who have/haven’t performed part of their training in the treatment of a patient with addiction.
Have you performed part of your psychiatric
training in the treatment of patients with addiction?
Yes No
Illicit drugs (e.g., heroin) addicted
are good people
Strongly agree 9 3 χ2 = 8.773
p = 0.067Agree 33 22
Neither agree or disagree 303 236
Disagree 101 52
Strongly disagree 62 60
I don’t feel confident with my
skills to work in addiction
Strongly agree 36 22 χ2 = 82.864
p < 0.001Agree 178 44
Neither agree or disagree 125 84
Disagree 146 181
Strongly disagree 23 42
I think that people with drug
addiction cannot recover
Strongly agree 138 88 χ2 = 3.872
p = 0.424Agree 257 188
Neither agree or disagree 87 75
Disagree 25 19
Strongly disagree 1 3
Addiction is a mental disorder Strongly agree 5 4 χ2 = 6.263
p = 0.180Agree 25 15
Neither agree or disagree 59 61
Disagree 262 198
Strongly disagree 15 95
Addiction psychiatrists are
usually less skilled than their
colleagues working in general
adult and child adolescent
psychiatry
Strongly agree 159 130 χ2 = 6.565
p = 0.161Agree 181 140
Neither agree or disagree 104 73
Disagree 57 24
Strongly disagree 7 6
was no significant difference in terms of the most prevalent
addiction-related condition that was treated/observed during
their addiction psychiatry training [F(4,479) = 1.523, p= 0.194].
However, those trainees who had treated alcohol withdrawal
syndrome, delirium tremens, opioid withdrawal syndrome, or
substance induced-psychosis were significantly more senior
in their level of training completeness, compared to those
trainees who had not treated these addiction-related conditions
who were more junior (all p-values < 0.001). Similarly, those
trainees prescribing acamprosate, naltrexone, methadone, and
buprenorphine were also significantly further in their training
than those who did not prescribe a medication for an addiction
(all p-values < 0.001). In addition, GAP trainees more likely
reported to have treated a person affected with an addiction
during their training, compared to CAP trainees [χ2(1) = 8.328,
p = 0.004]. Likewise, GAP trainees more likely reported to
have prescribed medication for an addiction-related condition,
compared to CAP trainees [χ2(1) = 9.482, p = 0.002].
Furthermore, GAP trainees reached higher scores, compared to
those undergoing CAP training, when questioned about their
general and specific knowledge of addictions [F(1,802) = 14.181, p
< 0.001]. Moreover, GAP trainees were more likely aware of the
existance of legal highs/smart drugs/novel substances, compared
to CAP trainees [χ2(2) = 25.663, p < 0.001]. However, when the
knowledge score includes in the analysis also those questions
about legal highs/smart drugs/novel substances, there was no
significant difference in the total score between GAP and CAP
trainees [F(1,531) = 0.524, p= 0.470].
DISCUSSION
Key Findings and Comparison With the
Literature
PSUD have been historically perceived as personal, family,
social, moral, or criminal issues rather than a health condition
(24). Therefore, subjects with PSUD have been supposed
to be better managed at the individual, family or justice
level (i.e., through existing social infrastructure or civil and
criminal justice interventions) (24). Indeed, criminalization of
people with PSUD exacerbated their perceived and experienced
stigma, avoidant attitudes and behaviors of contempt, by
worsening their marginalization and poor access to adequate
treatment and care (24). People with PSUD tend to be
stigmatized due to their use of drugs and drug-seeking
behaviors (24). Moreover, other PSUD-related risky behaviors,
such as speeding/dangerous driving, violence, aggressiveness,
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TABLE 3 | Attitude of trainees who have/haven’t known someone outside their workplace with addiction related problems.
I know/had known someone outside my workplace
(family, friends, relatives, neighborhood) who
has/had addiction related problems
Yes No
I am afraid to work with persons
with cocaine addiction
Strongly agree 204 39 χ2 = 14.623
p = 0.006Agree 309 101
Neither agree or disagree 92 42
Disagree 62 20
Strongly disagree 7 5
I am afraid to work with persons
with alcohol
Strongly agree 283 68 χ2 = 8.305
p = 0.081Agree 298 97
Neither agree or disagree 64 30
Disagree 25 11
Strongly disagree 4 1
Addiction is a mental disorder Strongly agree 8 1 χ2 = 14.525
p = 0.006Agree 34 6
Neither agree or disagree 83 37
Disagree 339 121
Strongly disagree 210 42
Individual psychotherapy should
be preferred in treating addiction
Strongly agree 14 1 χ2 = 12.680
p = 0.013Agree 125 45
Neither agree or disagree 236 93
Disagree 238 52
Strongly disagree 61 16
and impulse dysregulation, are barely seen as part of a
complex disorder, so that people with PSUD are usually
rejected by the society due to the supposed moral valence
of these behaviors (24, 25). These patients may also be seen
as a burden for the healthcare system, by indeed increasing
the disparities of cares, the risk to not adequately provide
evidence-based and effective treatments (19, 25). Due to
this disadvantageous framework, patients with PSUD may
develop a self-stigmatizing attitude as well (e.g., a subjective
process characterized by negative feelings about own self,
maladaptive behaviors, stereotype endorsement resulting from
individual’s experiences/perceptions/feelings and anticipation
of negative social reactions) (26–29). In fact, potentially
“stigmatized” attitudes and behaviors, overly provided by
healthcare professionals, including psychiatrists and psychiatry
trainees, may be potentially trigger and maintain these
self-stigmatizing attitudes, as already reported in the literature
and confirmed by our findings (16, 19, 26–29). Furthermore,
subjects with PSUD are symbolically associated with a range
of other stigmatized health conditions, including HIV/AIDS,
HCV, risk and disinhibiting behaviors such as impaired driving,
prodigality, criminality, risky sexual behaviors, and social issues
(30, 31). Stigmatizing beliefs and behaviors about PSUD may be
influenced by the level of knowledge (and education) about these
mental health conditions and the personal experience with people
affected with PSUD. Furthermore, it has been reported that
media portrayal of people with PSUD and media coverage/level
of news disseminated about significant and impactful related
events, mainly occurring due to a drug intoxication and/or
drug dependence/abuse/misuse, can significantly increase these
stigmatizing beliefs and attitudes (29, 32).
Furthermore, addictions have not been historically
recognized as conditions requiring a medical, psychological
and psychopharmacological treatment (19). This is in line
with our findings in which most GAP and CAP trainees
declared that the addictions are not mental disorders. In
fact, as previously documented in the literature, this overall
consideration regrading PSUD appears to be widely spread
not only at the general population level but also amongst
mental health professionals who overall reported negative
and pessimistic views about PSUD, people with PSUD
and do not routinely screen patients in daily practice for
addictions (15, 26, 33, 34).
However, the individual perceptions and attitudes towards
people with PSUDmay largely vary according to different factors.
For instance, people are less likely to endorse the stereotype
of violence together with a negative connotation of addiction
disorders, if they have had direct contact with people (or also
familymembers or close friends) whowere affected with PSUDor
did not experience violent acts by people affectedwith PSUD (35).
This is comparable with our findings which demonstrated that
those trainees who have/had experience with people with a PSUD
significantly declared to have a stronger desire to work in the
addiction field and with subjects with PSUD after their training.
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FIGURE 2 | Frequency of trainees who would like to work in addiction
following completion (by those who have/haven’t known someone outside the
workplace who has had an addiction related problem).
FIGURE 3 | Mean percentage of training completed in those who
have/haven’t worked with patients with psychoactive use disorders during
their training (by sub-specialty).
Furthermore, despite a compelling need for PSUD treatment
in Europe, mental healthcare professionals (including psychiatry
trainees) overall appear poorly or neither trained, nor especially
eager to accept/tolerate patients with PSUD (15, 33, 34, 36).
In general, psychiatrists do not feel competent/confident in
treating addiction disorders, do not like working with patients
affected with PSUD and do not find rewarding treating patients
with PSUD (33, 37, 38). A lack of (practical) experience
and/or an inadequate (theoretical and practical) training in
FIGURE 4 | Distribution of the knowledge score.
addiction psychiatry may indeed result in an endless loop of
incompetence and neglect regarding the addiction psychiatry,
amongst mental health care professionals. However, despite
the evidence demonstrating the need to improve addiction
medicine’s training not only amongst psychiatry trainees but
also amongst all physician trainees, most medical students and
CAP/GAP trainees generally receive an inadequate (practical and
theoretical) training in the field of addiction medicine/psychiatry
(33, 39, 40). Moreover, most CAP/GAP trainees generally
display lacking core clinical and therapeutic competences,
as required for working with patients with PSUD (33, 39,
40). Although formal addiction training within the medical
field has been closely tied to psychiatry, psychiatric training
generally provides a poor improvement and a limited level
of knowledge over medical school, about addictions (39,
40). These considerations are particularly significant in the
European countries, whereas there are several inequalities
and heterogeneous training levels in addiction psychiatry, as
documented by our findings. Furthermore, most CAP and
GAP trainees reported to be less skilled in the addiction field,
compared to other fields of psychiatry. Interestingly, there are
not statistically significant differences between GAP and CAP
trainees regarding this finding. This appears particularly relevant
if we consider that CAP trainees should possess a comprehensive
experience including behavioral, psychosocial and addiction
problems particularly amongst youngsters/adolescents who have
been well-demonstrated to be those patients more frequently
exposed to drugs and/or other addictive behaviors, but also
those patients more vulnerable toward the new onset of mental
disorders associated with a PSUD (41).
Furthermore, an insufficient training experience with patients
with PSUD, along with the lack of a highly-specialized
faculty (i.e., short addiction training experience, lack of a
supervisor/mentor during the addiction training, and poor
quality of addiction training), may overall lead to a discouraging
training experience amongst CAP/GAP trainees, as reported
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in our study. Overall, one could argue that this general
psychiatry trainees’ attitudes and perceptions towards the
addiction psychiatry might discourage trainees’ interest and
willingness to deepen the management and therapy of patients
with PSUD, independently by their level of psychiatry training,
as well as their interests in working in addiction psychiatry
(38). Renner et al. (38) described the following main predictors
of poor perception of careers in addiction medicine by GAP
trainees: (a) the poor/not enough/lacking experience with
patients with PSUD; (b) the perceived sensation and feeling
to work with “difficult” patients; (c) the lack of a competent
training in the addiction; (d) an overemphasis, during psychiatry
training, about the detoxification process rather than a long-
term rehabilitative and care program for the addiction-related
conditions. Miller et al. (33) identified the following hypothesized
barriers/determinants explaining the different attitudes and
practices of medical students, trainees and physicians towards
addiction psychiatry: (a) lack of acceptance of a medical model
for addictive disorders; (b) lack of positive and/or optimistic
attitudes about patients with PSUD, by accepting the prevalent
stereotype of subjects with PSUD as those patients whose social
and medical prognosis is poor; (c) curricula deficits throughout
the Continuum Medical Education (CME) in the field of
the addiction psychiatry/medicine, particularly the total time
devoted to addictive disorders during the medical school and
psychiatry training; (d) lack of parity and physician advocacy in
medical education; (e) prejudices and misunderstandings about
addictive disorders, along with ungrounded fears of huge costs
connected with addiction treatment and the perception that
addiction treatment owns a low ratio of benefits to costs; (f)
personal and/or family history of drug and/or alcohol disorders.
Conversely, Rush et al. (42) found that the factors associated
with more positive attitudes towards the treatment of addictive
disorders and subjects with PSUD may be represented by: (a) the
number of subjects with PSUD treated/visited; (b) the physicians’
perceived effectiveness in the management of the addictive
disorders; and, (c) the numbers of hours of CME specifically
addressed on the addictive disorders.
However, as widely reported in the literature, the level of
knowledge and education about PSUD and addiction psychiatry
can positively influencemental health professionals’ attitudes and
interests towards the field of addictions, limit the misdiagnosis
and potentially reduce improper and inadequate treatment
regimens for these disorders (43–45), even though other studies
demonstrated a deterioration in attitudes throughout medical
school years and suggested a continued decline throughout the
years of training, mainly due to time and resources spent for
those subjects with PSUD (19, 46–49). The enhancement of
these beliefs appears to be more significant when we compared
those subjects with PSUD with those with AUD (49). As
proposed by Miller et al. (33), to achieve an adequate level
of education and training in addiction psychiatry, it should
be ensured that all trainees reach an enough and adequate
knowledge and skills in the diagnosis and treatment of the
addictive disorders, by favoring the development of curricula for
the addictive disorders in all medical schools, residency training
programs and CME; by supporting the research and revising all
discriminatory policies that create barriers to the implementation
of curricula in addictive disorders; by providing the detection
and intervention for students, trainees and physicians who have
addictive disorders; and, by supporting the parity between the
addictive disorders and other medical and psychiatric diseases.
Main Strengths and Limitations
To the best of our knowledge, this has been the only study
specifically investigating the levels of training, experiences,
attitudes and perceptions as well as the level of perceived
confidence and capacity in the management of people with
a PSUD, carried out amongst European CAP/GAP trainees.
The present survey also included a large sample size of
CAP/GAP trainees in Europe (n = 1,118) which comprises
many European countries (n= 30). Furthermore, collecting data
from different European countries might lend strength to the
generalization of these findings also to other WHO Regions,
beyond European Region. Moreover, our study identifies gaps in
knowledge by demonstrating that addiction psychiatry appears
not to be adequately and homogeneously incorporated within
the psychiatric training, across all European countries. Moreover,
a key finding is represented by the significant number of
recruited psychiatry’s trainees who do not consider addiction as a
psychiatric disorder.
Despite its original and poorly investigated topic, there
are several limitations that should be here drawn up. Firstly,
being a self-report questionnaire and partly online administered,
potential recall, social desirability, and reporting biases may
occur. Secondly, the sampling method may be hugely affected
both by the fact that not in all European countries we reached
an enough number of completed questionnaires or reached an
available official national coordinator. In fact, some European
countries initially included have been a posteriori excluded in our
analysis as they did not reach an enough number of completed
questionnaires (cut-off of 10 for each country), like Greece,
Belgium, Germany, Slovakia, Ukraine, Sweden, Denmark, and
Israel. Furthermore, sampling rates largely vary within different
European countries, being some countries (i.e., Croatia, Finland,
France, Ireland, Italy, Lithuania, Poland, Portugal, Romania,
Slovenia, Spain, Turkey, and UK) most represented in our
sample compared to Albania, Bosnia, Bulgaria, Czech Republic,
Estonia, The Netherlands, Serbia, and Switzerland. The level of
perceived confidence and knowledge in addiction psychiatry,
being mainly based on a set of questionnaires, may also be
susceptible to the updated information and new available and
emerging pharmacological and not pharmacological treatments,
may not completely reflect the current situation occurring
at the time of writing of the present study. Moreover, the
present study does not examine what happens once GAP/CAP
residency is completed and the GAP/CAP enters career’s
practice. It should be relevant to document further data
particularly regarding the level of attitude or perception of
PSUD patients with added experiences and added continuing
educational opportunities during their clinical career. Finally,
the present study does not specifically define whether psychiatry
trainees’ attitudes differ towards caring for subjects with AUD
and/or SUD.
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Relevance of the Findings and Implications
for Practice, Policies, and Research
The present study provides significant and valuable information
on the current European CAP/GAP trainees’ level of experiences,
training, perceived knowledge/competence, and subjective
attitudes/perceptions towards the addiction psychiatry. These
findings not only serve to investigate the current European
situation in terms of level of subspecialty offered in the
addiction psychiatry as well as the potential differences across
all analyzed European countries, but they might also investigate
those situations which should be implemented/enhanced as
lacking in providing opportunities both in terms of internship
(practical training) and knowledge (theoretical training) in
the field of the addictions. Moreover, addressing the identified
reasons/factors determining a different level of training in
addiction psychiatry as well as a different level of interest
CAP/GAP trainees, in strenghtening knowledge in this field
might be a way to modulate and act on these factors, to improve
the CAP/GAP training conditions in the field of addiction
psychiatry (50). Regarding the need to improve all CAP/GAP
training programmes, the standardization of curricula would
be important to produce both GAP and CAP trainees able
and capable (self-confident) in the management and correct
identification of both physical and mental/behavioral PSUD-
related conditions. This should be part of the essential core
knowledge that should be indispensable for all psychiatric
practice. In terms of the enhancement of GAP/CAP trainees’
education/knowledge in the addiction medicine and psychiatry,
an implementation of a mandatory addiction rotation during
the CAP and GAP training program, could greatly improve
the level of trainees’ confidence and competence in identifying
and dealing with all different addictive disorders. Furthermore,
in CAP and GAP training, the need to develop and satisfy
objective measurable educational criteria must be balanced
with the acquisition of subjective skills needed to treat subjects
with PSUD effectively (e.g., increasing empathy and not
judgmental approach as well as addressing stigma), as well as
reaching an enough comfort in working with PSUD patients
and obtaining a minimum sense of mastery in the field of
the addictions. Finally, it might be suggested to all European
GAP and CAP training programmes to administer to all
psychiatry trainees at the end of their training program, validated
tools for assessing addiction psychiatry training and early
identify potential deficits, such as the Addiction Training
Scale (ATS) (51).
These findings may assist the decision-makers to implement
strategies to adapt their national diversities in CAP/GAP training
programmes and make them homogenous especially at the
European level. The need for psychiatry trainees’ education
and experience in treating patients with addiction problems
has been outlined. Lastly, although these preliminary findings
may help in mapping the reality of this field of psychiatry,
further studies are needed to focus on the main motivations
underpinning the existing differences across European countries
in terms of level of training in addiction psychiatry (i.e.,
cultural and/or religious factors, epidemiological motivations,
etc.) and consequences of different experiences/training in the
level of knowledge of a CAP/GAP trainees as well as their
attitude/perception towards addictions in general and people
who use psychoactive substances. Moreover, it would also
be of interest to repeat the present survey with identical
methodology every 4 or 5 years (being the average duration
of CAP/GAP European training) to assess potential trends
in these findings and attitudes/opinions of psychiatry trainees
over time and evaluate if any enhancing intervention has been
provided at European and national level concerning addiction
psychiatry training and evaluate if any positive/neutral/negative
impact was reached amongst psychiatry trainees’ attitudes
and knowledge.
CONCLUSIONS
Despite the growing dissemination of addictive disorders across
all European countries, addiction psychiatry seems to be an
underdeveloped part of psychiatry within psychiatry training
programmes. However, we found substantial consensus among
all European psychiatry trainees that more education and
experience in treating patients with addictive disorders should be
guaranteed and be part of the core curricula in GAP and CAP
training. Further research needs to be directed towards the causes
of poor training as well as timings of these educational activities
to optimize experiential education programs to be implemented
within GAP and CAP training programs.
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